Nasdaq
$4.39▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $170.4MShares out 38.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
22- 10.14Pre-market26.10.14 20:528-KKey event#●●●#●●●#●●●
Entrada Therapeutics, Inc.Bullish
Entrada Therapeutics announced positive safety and tolerability data from Cohort 1 of the Phase 1/2 ELEVATE-45-201 study for its DMD candidate ENTR-601-45. Treated participants showed a mean increase of 0.10% in dystrophin production from baseline, and the company plans to report data from Cohort 2 in the first half of 2027.…more
$4.39+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.10After-hours26.09.11 05:26SCHEDULE 13D/AOwnership
Entrada Therapeutics, Inc.
Investment entities affiliated with MPM BioImpact sold shares of Entrada Therapeutics, Inc. (TRDA) in the open market between August 24 and September 9, 2026. The reporting persons reduced their holdings by selling shares at average prices ranging from $6.99 to $7.54 per share.…more
$4.39+0.00%vs prev closeView filingShare - 9.9After-hours26.09.10 08:244Ownership
Entrada Therapeutics, Inc.
Major shareholders of Entrada Therapeutics, including MPM BioVentures 2018, L.P. and its affiliates, filed a Form 4 report regarding changes in their beneficial ownership as of September 4, 2026. This filing reflects updates to the equity holdings of these reporting entities.…more
$4.39+0.00%vs prev closeView filingShare
21 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoPre-market26.10.21 20:00#●●●#●●●
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
Entrada Therapeutics has appointed Linea Aspesi as Chief People Officer to support organizational scaling and culture development. This executive appointment is a routine management move and is expected to have a neutral impact on the stock.…more
$4.39+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.14Regular26.10.15 01:47
●●●●●●●● ●●●●● ●●●●●●
Entrada Therapeutics shares fell over 15% after reporting initial Phase 1/2 trial results for its Duchenne muscular dystrophy candidate that showed safety but no immediate functional benefits. The company plans to test higher doses in future cohorts to demonstrate meaningful efficacy.…more
$4.39+0.00%vs prev closeShareBenzinga - 10.14Pre-market26.10.14 20:00
●●●●●●●● ●●●●● ●●●●●●
Entrada Therapeutics has received approval from an independent committee to initiate the third cohort at the highest dose for its Phase 1/2 study of ENTR-601-44. The company expects to report data from the first and second cohorts by the end of 2026 and the first quarter of 2027, respectively.…more
$4.39+0.00%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report